FT576 in Subjects With Multiple Myeloma
Public ClinicalTrials.gov record NCT05182073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Study identification
- NCT ID
- NCT05182073
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Interventions
- FT576 (Allogenic CAR NK cells with BCMA expression) Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- Daratumumab Drug
- Bendamustine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2021 (Actual)
- Primary completion
- Sep 20, 2024 (Actual)
- Completion
- Oct 18, 2024 (Actual)
- Last update posted
- Dec 12, 2025
2021 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35205 | — |
| City of Hope | Duarte | California | 91010 | — |
| Scri-Cbci | Denver | Colorado | 80218 | — |
| Medical Oncology Hematology Consultants | Newark | Delaware | 19713 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| University of Minnesota | Saint Paul | Minnesota | 55108 | — |
| Washington University | St Louis | Missouri | 63130 | — |
| Roswell Park | Buffalo | New York | 14263 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Oncology Hematology Care, Inc | Cincinnati | Ohio | 45226 | — |
| Tennessee Oncology - Nashville | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Medical City Dallas | Dallas | Texas | 75230 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05182073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05182073 live on ClinicalTrials.gov.